RxDoctor Payments Data

Gregory Lund, MD

Endocrinology, Diabetes & Metabolism · Denver, CONPI 1265468342

Payments from drug & device makers

$1,074in general payments, 2019–2025

Across 60 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$189
  • Medtronic$163
  • Lilly USA, LLC$121
  • AbbVie$91
  • Tandem Diabetes Care, Inc.$90
  • BETA Bionics, Inc.$55
  • plus $364 from 12 others

What the payments were for

  • Food & beverage$1,06299%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,074 in reported general payments places this provider in the 45th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

See all endocrinology, diabetes & metabolism providers in Colorado

Medicare billing

Part B allowed, 2024
$58,455
Medicare patients
243
Services billed
661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide241$314,199
TrulicityDulaglutide219$299,951
JardianceEmpagliflozin205$203,215
OzempicSemaglutide138$169,386
Tresiba Flextouch U-200Insulin Degludec144$161,868
JanuviaSitagliptin Phosphate97$88,486
Humalog Kwikpen U-200Insulin Lispro34$81,046
FarxigaDapagliflozin Propanediol53$70,435
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog30$44,660
Humalog Kwikpen U-100Insulin Lispro101$32,917
Fiasp FlextouchInsulin Aspart (Niacinamide)25$29,705
TradjentaLinagliptin20$25,626
Tresiba Flextouch U-100Insulin Degludec47$24,876
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/721$22,343
Lantus SolostarInsulin Glargine,hum.Rec.Anlog122$20,777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro$121$634,810517 claims
Novo NordiskOzempic$189$169,386138 claims
AstraZenecaFarxiga$54$70,43553 claims
Sanofi-aventis U.S. LLCLantus, Admelog$36$7,72870 claims
AbbVieSynthroid$91$6,07172 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$3,652435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

Other endocrinology, diabetes & metabolism in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →